BD (Becton, Dickinson and Company) announced its fiscal 2025 second quarter results on May 1, 2025, reporting total revenues of $5.272 billion. This represents a 4.5% increase as reported and 0.9% organic growth year-over-year, with organic growth falling below expectations due to market dynamics in the Life Sciences segment.
Adjusted diluted earnings per share for Q2 FY25 were $3.35, a 5.7% increase from the prior-year period, exceeding expectations. However, reported diluted EPS decreased by 42.2% to $1.07. The company noted that strong operational performance, driven by gross margin improvement, helped offset some market-driven revenue softness.
BD updated its full-year fiscal 2025 guidance, revising organic revenue growth to 3.0% to 3.5% from the previous 4.0% to 4.5%. Total revenues are now projected between $21.8 billion and $21.9 billion. The company also lowered its Adjusted Diluted EPS guidance to a range of $14.06 to $14.34, down from $14.30 to $14.60, primarily due to an estimated $0.25 impact from tariffs.
The estimated tariff impact is based on information available as of April 30, with BD warning that international trade policies are rapidly evolving. Despite the lowered revenue growth, BD stated that strong operational performance is expected to largely offset the earnings impact of the revised organic sales growth before accounting for tariffs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.